Back to discover
Drug

Ticagrelor

Approved · EMA
ClassPurinergic receptor P2Y12 negative allosteric modulatorEmerging researchLate-stage developmentRising momentum

Also known as Brilinta, Brilinta (ticagrelor), (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

RxNorm1116632ChEMBLCHEMBL398435ATCB01AC24UNIIGLH0314RVC
4
Research papers
13
Active clinical trials
P2Y purinoceptor 12
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial

Clinical trial2026-07-28Results expected Q2 2027 · ClinicalTrials.gov

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)

Clinical trial2026-07-11Primary completion · ClinicalTrials.gov

Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease

Clinical trial2026-05-29Results expected Q2 2027 · ClinicalTrials.gov

Hunting for the Long-Term EffeCts of P2Y12 Inhibitor monotHerapy and Coagulation Monitoring After PCI: an Open-label, Randomized Study.

Clinical trial2026-05-13Results expected Q2 2028 · ClinicalTrials.gov

The Use of Thromboelastography With Platelet Mapping to Guide Thromboprophylaxis Following Lower Extremity Revascularization for Peripheral Artery Disease

Clinical trial2026-02-17Primary completion · ClinicalTrials.gov

Pharmacodynamic Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention Who Are At Risk of Peri-PCI Myocardial Infarction Using a Precision Medicine Tool

Clinical trial2026-02-05Results expected Q4 2026 · ClinicalTrials.gov

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study

Clinical trial2026-02-05Results expected Q3 2026 · ClinicalTrials.gov

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.

Research2020-06-01JAMA

A Genotype-Guided Strategy for Oral P2Y<sub>12</sub> Inhibitors in Primary PCI.

Research2019-09-03The New England journal of medicine

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.

Research2019-09-01The New England journal of medicine

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

Research2014-09-01The New England journal of medicine

Approval: Brilique (EMA)

Regulatory2010-12-03EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ticagrelor
Aliases & brands
BrilintaBrilinta (ticagrelor)(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
RxNorm CUI
1116632
ChEMBL ID
CHEMBL398435
ATC codes
B01AC24
UNII
GLH0314RVC
Primary mechanism
Purinergic receptor P2Y12 negative allosteric modulator
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

P2Y purinoceptor 12
P2RY12 · Q9H244
NEGATIVE ALLOSTERIC MODULATORPurinergic receptor P2Y12 negative allosteric modulator

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2010-12-03
Latest approval
2010-12-03
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2010-12-03Approval
Approval: Brilique (EMA)
Indication: Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a… Show full indication

Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

184 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
184
registered trials across all phases
LATEST COMPLETION 2025
13
Active studies
12
Recruiting
151
Late-stage (III+)
112
Completed
59
Discontinued
PHASE DISTRIBUTIONn = 184
Early Phase 11Phase 111Phase 1 / 24Phase 217Phase 2 / 36Phase 339Phase 493Phase N / A13

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial

RecruitingPH IVKey trialFundacin Biomedica Galicia Surn=1,2062028

Pharmacodynamic Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention Who Are At Risk of Peri-PCI Myocardial Infarction Using a Precision Medicine Tool

RecruitingPH IVUniversity of Floridan=502027

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study

RecruitingPH IVUniversity of Floridan=482026

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)

RecruitingPH IVKey trialMedical University of Gdanskn=1,1942026

Safety and Efficacy of Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After Drug-coated Balloons for Coronary Small Vessel Disease: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation, Single-center Study

Unknown statusPH IVFu Wai Hospital, Beijing, Chinan=2922025

Recent completions

Trials that read out recently, adding to the completed evidence base.

Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome-a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry

CompletedPH IVKey trialVastra Gotaland Regionn=17,0952025

Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction - A Prospective Single-centre, Single-arm Phase II Study

CompletedPH IIVastra Gotaland Regionn=2002025

Twice a Day Clopidogrel vs Ticagrelor in Reducing Major Cardiac Events in Patients With Acute STEMI Undergoing Primary Percutaneous Intervention- TADCLOT- a Double Blind Randomized Controlled Trial

CompletedPH IIIKey trialNational Institute of Cardiovascular Diseases, Pakistann=2,2002025

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 Study

CompletedPH IVUniversity of Floridan=812025

A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects with Multiple Administration of Tiprogrel

CompletedPH ITianjin Institute of Pharmaceutical Research Co., Ltdn=142024

An Open-label, Randomised, Parallel-group, Fixed-sequence Study to Assess the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

CompletedPH IAstraZenecan=282024

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20142020
Major research themes3
Emergency Medical Services1Genotype1Percutaneous Coronary Intervention1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine3
  • JAMA1
Leading researchers
  • Hamm CW2
  • Ahn CM1
  • Akin I1
  • Allali A1
  • Angiolillo DJ1
  • Antoniucci D1
  • Asselbergs FW1
  • Baradat C1
Leading institutions
free-text, unnormalised
  • and Technische Universität München (S.S.1
  • Dankook University Hospital1
  • Gangnam Severance Hospital1
  • Gangneung Asan Hospital1
  • Kangwon National University School of Medicine1
  • Myongji Hospital1

Related diseases

3 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Prasugrel Hydrochloride

Acts on the same molecular target as Ticagrelor, with 6 overlapping disease areas.

Shared target6 shared diseases2 shared papers
Aspirin

Studied across 6 of the same disease areas as Ticagrelor in the shared literature.

6 shared diseases1 shared paper
Clopidogrel

Studied across 4 of the same disease areas as Ticagrelor in the shared literature.

4 shared diseases1 shared paper
Sirolimus

Studied across 4 of the same disease areas as Ticagrelor in the shared literature.

4 shared diseases1 shared paper
Ticlopidine

Studied across 3 of the same disease areas as Ticagrelor in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.